drugset / Trial / NCT03667326

Postpartum Low-Dose Aspirin and Preeclampsia

NCT03667326

Phase 2 Recruiting 100 enrolled Columbia University
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.

Timeline

Start
2019-07-22
Primary completion
2026-06
Completion
2026-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 81 mg Oral

Indications